(Date:5/16/2008)...National HIV Vaccine Awareness Day, May,18, WASHI...x years into the,AIDS epidemic, someone is newly i...unday, May 18, HIV Vaccine Awareness Day, AIDS Act... Institute of Allergy and Infectious,Disease (NIAI...s everyone,to help end the AIDS epidemic by partic...
(Date:5/16/2008)...untsworth plc (LSE: HNT), "the Group",a leading i...nications,group headquartered in London, released ...Group,s performance in the first quarter 2008 (the...follows below., 15 May 2008, ...erim Management Statement, Record net ...
(Date:5/16/2008)... More in 2007, WASHINGTON, May 16 /PRNewswire-USN...cancer deaths, the National Cancer Institute (NCI)...in lung cancer research in 2007,according to upda...) today., The two other federal agencies with sig...isease Control and Prevention (CDC) and the,Depart...
(Date:5/16/2008)...Comprehensive Income increased 42% to $9.7 million... - 2007 Gross Margin of 76%, - Product Sales Back... million from $2.4 million as of December 31, 200...stCall/ -- Huiheng,Medical, Inc. ("Huiheng" or the...sed leader in the development, sales and support o...
Breaking Medicine News(10 mins):Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 2Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 3Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 4Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 5Health News:Huiheng Medical, Inc. Reports Record Financial Results for Fiscal Year 2007 and Financial Results for Q1 2008 6(Date:5/15/2008)...ssure reductions demonstrated in Blacks, Hispanics...d Obese Individuals, PARSIPPANY, N.J., May 15 /PR... that data presented at the American Society of,Hy...ng (ASH 2008) in New,Orleans demonstrated that the...d olmesartan medoxomil) safely and effectively hel...
(Date:5/15/2008)...ZELL, Switzerland, May 15 /- Ergonex ... and Drug Administration (FDA) has,granted orphan ... pulmonary,arterial hypertension (PAH). Terguride ...Phase II trial in Europe., "The FDA,s grant of or...ges and strengthens our development program by off...
(Date:5/15/2008)...ble Opportunity Remains for an Antiplatelet Therap...ng than the Combination of Plavix/Iscover and ...esources, WALTHAM, Mass., May 15 /- ...earch and advisory firms for pharmaceutical and,he...ly,s Effient offers,improvement in patient compare...
(Date:5/15/2008)... Presented at the 21st Annual Meeting of The Ameri...ology (ASPHO) Meeting -, IRVINE, Calif., May 15 /...pany) (Nasdaq: IDMI ) today announced the present...program evaluating mifamurtide (L-MTP-PE) in,patie...ssion of,osteosarcoma, a rare and often fatal bone...
Breaking Medicine Technology:Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6HRSA Proposes Rule to Revise Combine HPSAs MUPs 13549 1HRSA Proposes Rule to Revise Combine HPSAs MUPs 13549 2MinuteClinic Hits 500th Clinic Mark 3B New Locations Open in Dallas Los Angeles and Orlando CVS pharmacy Stores 13545 1MinuteClinic Hits 500th Clinic Mark 3B New Locations Open in Dallas Los Angeles and Orlando CVS pharmacy Stores 13545 2MinuteClinic Hits 500th Clinic Mark 3B New Locations Open in Dallas Los Angeles and Orlando CVS pharmacy Stores 13545 3Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 1Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 2High Numbers of Children With Special Needs Have Health Insurance Regular Caregivers HRSA Survey Finds 13539 1High Numbers of Children With Special Needs Have Health Insurance Regular Caregivers HRSA Survey Finds 13539 2...7 - PrimeCell(TM),Therapeutics LLC (http://www.pri...ovided research support and pre-clinical,studies f...ity and,efficacy of implanting autologous bone mar...nts., Dr. Luis Geffner presented a preliminary rep...l Society for Cellular Therapy,held here June 24-...
...centia,Biopharmaceuticals, Inc. (NASDAQ: ABPI) ann...thcare Conference that its interim,analysis of the...ast-Tracked Phase 3 clinical study of SinuNase(TM)...substantial improvement in,resolution of one or bo...and substantial improvement in intranasal polyposi...
Other Medicine Technology:Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for,Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical,Study 2Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 2Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 3Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 4...uum Controller V-800 Efficiently controls vacuum...s V-500 on and off as needed to maintain preset va...ane vacuum pump designed to handle most vacuum app...with up to two rotary evaporators Laboratory vac...
...cooled secondary condenser to trap residual solven...acuum pump designed to handle most vacuum applicat...up to two rotary evaporators Laboratory vacuum s...entrators, gel dryers, and filtration apparatuses ...
...0 is a multi-tasking vacuum source and solvent rec...apor trap and a maintenance-free, oil-free vacuum ... wide-mouth glass condensation flask collects all ...posal. The UVS400 provides an ideal vacuum system ...
Universal vacuum pump (capacity 34 L/min, 8 mbar vacuum abs.)
Medicine Products: